Ellipsis Health's AI Technology Will Allow Healthcare Providers
Using Augmedix to Seamlessly Screen Patients for Symptoms of
Anxiety and Depression
SAN
FRANCISCO, Oct. 5, 2023 /PRNewswire/ -- Ellipsis
Health, the market leader in AI-generated vocal biomarker
technology for the identification and monitoring of mental health
conditions at scale, today announced a plan for a strategic
partnership with Augmedix (Nasdaq: AUGX), a healthcare technology
company that delivers industry-leading, ambient medical
documentation and data solutions. The partnership between the
parties will mark a significant milestone in healthcare delivery
and will allow healthcare providers using Augmedix to
incorporate mental health screenings during their clinical
encounters, helping to identify issues earlier and triage patients
to the appropriate care.
This comes at a critical time. Approximately half the world's
population is expected to develop at least one type of mental
health disorder by the age of 75. However, the average delay
between onset of symptoms and treatment is 11 years and over 50% of
people suffering from mental health conditions do not receive
treatment. Untreated mental illness costs the U.S. nearly
$300 billion annually. Augmedix
and Ellipsis Health are partnering to address these growing
problems, leveraging AI technology to create a more efficient and
cost-effective way of automating medical documentation and
screening for mental health at scale.
Augmedix plans to integrate the Ellipsis Health application
programming interface (API) into its platform so that alongside
ambient medical documentation, providers will receive the patient's
anxiety and depression severity scores during the visit. These
additional mental health structured data points will give providers
the ability to recommend an appropriate care pathway, such as a
referral to behavioral health or a digital intervention, connecting
patients with the right care at the right time. The technology can
also provide topic analysis, helping providers to document and
address concerns about their patients' social determinants of
health (SDOH), allowing for better whole-person care.
Both Augmedix and Ellipsis Health help eliminate lengthy
administrative work, saving providers time and allowing them to
focus their attention on putting the clinician-patient relationship
front and center. The addition of Ellipsis Health's AI-generated
voice biomarker tool to the Augmedix platform will enable providers
to move away from outdated, time-consuming, and non-personalized
surveys like the PHQ-8 and GAD-7, and have an easy, efficient way
to gain an even greater understanding of each patient's overall
health, leading to better treatment and patient outcomes.
"Augmedix and Ellipsis are well-positioned to collaborate to
further address the increasing need for mental health services,"
shared Ian Shakil, Founder,
Director, and Chief Strategy Officer of Augmedix. "Working hand in
hand with Ellipsis Health will allow us to realize the vision of a
clinician-patient encounter that not only is automatically
documented but also seamlessly supported with ambient point-of-care
technology tools and insights."
"We are excited to begin a partnership with a pioneer in the
health technology space that shares our commitment to improving
patient outcomes and making healthcare more efficient," said
Mainul Mondal, Founder & CEO of
Ellipsis Health. "Together, we are working to innovate the way
mental health is diagnosed and treated. For providers, using
Augmedix with Ellipsis Health's mental health screening tool is
like having a mental health copilot supporting care during every
visit."
Ellipsis Health and Augmedix have reached an agreement in
principle on a strategic collaboration to innovate and expand
access to healthcare and are working towards a definitive agreement
between the parties. Both companies are committed to the ethical
and responsible use of AI technology and look forward to expanding
its use within health systems to improve patient care.
About Ellipsis Health
Ellipsis Health is a healthcare
technology company that uses AI-generated vocal biomarker
technology to harness the human voice for earlier and better
identification, assessment, and monitoring of clinical anxiety and
depression. Through partnerships with providers, payers, and
digital health companies, Ellipsis Health is working to positively
impact the quality of mental health care, shorten the time to
diagnosis, drive workflow efficiencies, reduce costs, and improve
patient outcomes. The company was founded in 2017 and is backed by
leading investors including Khosla Ventures, SJF Ventures, and
Greycroft Ventures.
Ellipsis Health is headquartered in San Francisco, CA. To learn more, visit
ellipsishealth.com
About Augmedix
Augmedix (Nasdaq: AUGX) delivers
industry-leading, ambient medical documentation and data solutions
to healthcare systems, physician practices, hospitals, and
telemedicine practitioners.
Augmedix is on a mission to help clinicians and patients form a
human connection by seamlessly integrating our technology at the
point of care. Augmedix's proprietary platform digitizes the
natural clinician-patient conversations, which are converted into
comprehensive medical notes and structured data in real time. The
company's platform uses automatic speech recognition and natural
language processing, including large language models, to generate
accurate and timely medical notes that are transferred into the
EHR.
Augmedix's products relieve clinicians of administrative burden,
in turn, reducing burnout, increasing clinician efficiency and
improving patient access. Through Augmedix's proprietary platform
and bi-directional communication channel, Augmedix is ideally
suited to serve as the vehicle for change at the point of care.
Augmedix is headquartered in San
Francisco, CA, with offices around the world. To learn more,
visit www.augmedix.com.
Ellipsis Health Media Contact
Name:
Rebecca Unger
Email: rebecca@thenewnewthing.co
Augmedix Media Contact
Name: Kaila Grafeman
Email: pr@augmedix.com
Phone: (888) 669-4885
Forward-Looking Statement
This press release contains
"forward-looking statements" that involve a number of risks and
uncertainties. Words such as "believes," "may," "will,"
"estimates," "potential," "continues," "anticipates," "intends,"
"expects," "could," "would," "projects," "plans," "targets,"
"excited," "optimistic," and variations of such words and similar
expressions are intended to identify forward-looking statements.
Such forward-looking statements include, without limitation,
statements regarding the agreement in principle between Ellipsis
Health and Augmedix leading to a definitive agreement between
the parties; statements regarding the expectation that Ellipsis
Health and Augmedix will enter into a definitive strategic
partnership agreement; statements regarding the significance and
benefits of any partnership between Ellipsis Health and Augmedix,
including that it will allow healthcare providers to identify
issues earlier and triage patients to the appropriate care;
statements regarding Augmedix and Ellipsis Health leveraging AI
technology to create a more efficient and cost-effective way of
automating medical documentation and screening for mental health at
scale; statements regarding Augmedix's plans to integrate the
Ellipsis Health API into its platform and the expected benefits of
such integration; statements regarding Augmedix and Ellipsis Health
helping to eliminate lengthy administrative work, saving providers
time and allowing them to focus their attention on putting the
clinician-patient relationship front and center; and statements
regarding Augmedix and Ellipsis being well-positioned to
collaborate to further address the increasing need for mental
health services. Actual results could differ materially from those
stated or implied in forward-looking statements due to a number of
factors, including but not limited to, the ability of Ellipsis
Health and Augmedix to enter into a definitive agreement consistent
with the agreement in principle between the parties (if at all) and
the risks detailed in our most recent Form 10-K filed with the U.S.
Securities and Exchange Commission on April
17, 2023, as well as other documents that may be filed by us
from time to time with the U.S. Securities and Exchange Commission.
The forward-looking statements included in this press release
represent our views as of the date of this press release. We
undertake no intention or obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise. These forward-looking statements should
not be relied upon as representing our views as of any date
subsequent to the date of this press release.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ellipsis-health-and-augmedix-to-partner-to-bring-automated-mental-health-screenings-to-patient-visits-301947808.html
SOURCE Ellipsis Health